51 min ago | Medgadget
EDAP TMS of Vaulx-en-Velin, France received CE Mark approval for its Focal - One robotic High-Intensity Focused Ultrasound system for non-invasive treatment of prostate cancer.
4 hrs ago | SeacoastOnline
The Maine Coalition to Fight Prostate Cancer has been a strong advocate for prostate cancer screening for most men.
5 hrs ago | PhysOrg Weblog
Young women who have cancer treatment often lose their fertility because chemotherapy and radiation can damage or kill their immature ovarian eggs, called oocytes.
9 hrs ago | CiteULike
To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.
Dear Dr. Roach : In 2008, I was treated for prostate cancer with radiation. A couple of months later, I started passing blood during bowel movements.
Illnesses are a rather private thing, but I am persuaded that in this case what happened to me, and the good fortune that I was blessed with in terms of having a level headed and perceptive chum or two and an excellent GP, might well apply to a number of you.
Prostate cancer occurs in African-American men 60 percent more often than Caucasian men, and when they are diagnosed, it's more likely to be in advance stages.
Watching and routinely examining men with early, slow-growing prostate cancer is more effective and cheaper than sending them to surgery or radiation right away, according to a new study.
Newswise - A new drug called pyrvinium pamoate inhibits aggressive forms of prostate cancer that are resistant to standard drugs, according to a study conducted in an animal model.
A new drug called pyrvinium pamoate inhibits aggressive forms of prostate cancer that are resistant to standard drugs, according to a study conducted in an animal model.
Franciscan St. Francis Health Cancer Center today is the first medical facility in Indiana to use a new drug to treat men with advanced prostate cancer.
Riders participating in the annual Rally for Dad depart the Northeast Cancer Centre and make their way up Paris Street.
By Staff Writer - Vernon Morning Star Published: June 17, 2013 11:00 AM Updated: June 17, 2013 11:45 AM The event at Coldstream Ranch raised a record $38,500 Sunday.
Under the agreement, expected to close during the third quarter, J&J will pay $650 million upfront and potential milestone payments of up to $350 million for Aragon, which focuses on hormonally-driven cancers.
This morning, Johnson & Johnson announced it would buy Aragon Pharmaceuticals for as much as $1 billion.
Johnson & Johnson, the world's biggest maker of health-care products, agreed to pay as much as $1 billion to buy Aragon Pharmaceuticals Inc. and gain the closely held company's experimental prostate cancer drug.
Mount Sinai researchers present new data at ENDO 2013, The Endocrine Society's Annual Meeting & Expo June 15-18 in San Francisco Researchers from the Icahn School of Medicine at Mount Sinai will present several new studies at ENDO 2013, The Endocrine Society's Annual Meeting & Expo from June 15-18 in San Francisco.
As the incidence of prostate cancer continues to rise steeply, there is an increasing need to identify more accurate prognostic markers for the disease.